Interview with Ralf Vayntrub, Founder & President, Invar
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Address: 2 Ploshchad Zhuravleva, bld.2, 107023 Moscow,Russia
Tel: +7 (495) 962-16-62
Web: http://www.invarpharma.com/
INVAR is the Russian, privately-owned, national pharmaceutical & biotechnology company forming a product portfolio on the basis of
long-term exclusive in-licensing or distribution agreements on marketing and sales for the Russian market with owners of innovative medicines.
Number of employees – 104
Activity areas: Gynecology and Obstetrics, Dermatology, Otolaryngology, Pediatrics
Areas of interest: Innovative original pharmaceuticals, preferably in the spheres of dermatology, gynecology, otorhinolaryngology (ENT) and pediatrics
Company geography: Representation in 15 key regions of the Russia
Our dedicated team performs all key business processes:
• Regulatory & Clinical Affairs
• Marketing
• Sales Forces Organization
• Logistics & Supply Chain
• Commercial Operations
Products: Fluomizin, Gynoflor E (Medinova, Switzerland), Sinuforte (Hartington S.L., Spain), Epigen (Cheminova S.A., Spain), Skin Cap (Cheminova S.A., Spain)
Services: Registration, promotion and distribution of innovative pharmaceutical products within the territory of the Russia
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
